Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
How did WXXWY's recent EPS compare to expectations?
The most recent EPS for WuXi Biologics (Cayman) Inc. is $, expectations of $.
How did WuXi Biologics (Cayman) Inc. WXXWY's revenue perform in the last quarter?
WuXi Biologics (Cayman) Inc. revenue for the last quarter is $
What is the revenue estimate for WuXi Biologics (Cayman) Inc.?
According to of Wall street analyst, the revenue estimate of WuXi Biologics (Cayman) Inc. range from $ to $
What's the earning quality score for WuXi Biologics (Cayman) Inc.?
WuXi Biologics (Cayman) Inc. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does WuXi Biologics (Cayman) Inc. report earnings?
WuXi Biologics (Cayman) Inc. next earnings report is expected in 2026-06-22
What are WuXi Biologics (Cayman) Inc.'s expected earnings?
WuXi Biologics (Cayman) Inc. expected earnings is $, according to wall-street analysts.
Did WuXi Biologics (Cayman) Inc. beat earnings expectations?
WuXi Biologics (Cayman) Inc. recent earnings of $ expectations.